AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition

The emergence of EGFR inhibitors such as gefitinib, erlotinib, and osimertinib has provided novel treatment opportunities in EGFR-driven non-small cell lung cancer (NSCLC). However, most patients with EGFR-driven cancers treated with these inhibitors eventually relapse. Recent efforts have identifie...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2017-03, Vol.23 (6), p.1531-1541
Hauptverfasser:	Scarborough, Hannah A, Helfrich, Barbara A, Casás-Selves, Matias, Schuller, Alwin G, Grosskurth, Shaun E, Kim, Jihye, Tan, Aik-Choon, Chan, Daniel C, Zhang, Zhiyong, Zaberezhnyy, Vadym, Bunn, Paul A, DeGregori, James
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Anticancer properties Antitumor activity Cancer Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Cell Line, Tumor Cell Proliferation - drug effects Drug Resistance, Neoplasm - genetics Drug Synergism Enzyme Inhibitors - administration & dosage Epidermal growth factor receptors ErbB Receptors - antagonists & inhibitors Evaluation Experimental design Gefitinib Gene expression Humans Impingement Inhibition Inhibitors Kinases Lung cancer Lungs Mice Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - genetics Neoplasm Recurrence, Local - pathology Non-small cell lung carcinoma Pharmacodynamics Pharmacology Quinazolines - administration & dosage Signal transduction Signaling Tankyrases - antagonists & inhibitors Transcription Tumors Wnt protein Wnt Signaling Pathway - drug effects Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!